Current Report Filing (8-k)
09 May 2020 - 7:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 4, 2020
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36714
|
|
46-2956775
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
201 Mission Street, Suite 2375
San Francisco, California
|
|
94105
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.0001 Per Share
|
JAGX
|
The NASDAQ Capital Market
|
Item 7.01 Regulation FD Disclosure.
On
May 4, 2020, Jaguar Health, Inc. (the “Company”) received a letter from the Committee on Oversight and
Reform of the U.S. House of Representatives (the “Committee”) regarding the list price adjustment of Mytesi® (crofelemer).
Among other things, the Committee expressed an interest in understanding whether the price adjustment was connected to the
Company’s expectation that it could market crofelemer to treat coronavirus patients given the Company’s
submission of a request to the U.S. Food and Drug Administration (“FDA”) for Emergency Use Authorization
(“EUA”) for crofelemer (Mytesi®) for the symptomatic relief of diarrhea and other gastrointestinal
symptoms in patients with COVID-19 and for patients with COVID-19 who have diarrhea associated with certain antiviral
treatments, which submission was denied by the FDA on April 7 as previously disclosed.
The Company intends to cooperate with
the Committee’s inquiry and has prepared a public statement regarding the price adjustment, which is available on the
Company’s website at https://jaguarhealth.gcs-web.com/company-statement. In its statement, the Company explains that
the decision to adjust the price for crofelemer was made in December 2019 as part of expanding the Company’s
comprehensive patient access program, and had the Company received EUA, it would have deferred the price adjustment until
after the emergency use period ended.
A
copy of the Company’s statement is furnished as Exhibit 99.1 hereto and
is incorporated herein by reference. The information in this Item 7.01 and in Exhibit 99.1 to this Current Report on Form
8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, or otherwise
subject to the liabilities thereof, nor shall it be deemed to be incorporated by reference in any filing under the Securities
and Exchange Act of 1934 or under the Securities Act of 1933, except to the extent specifically provided in any such filing.
Item 8.01 Other Events.
The information in the first paragraph of Item 7.01 above relating
to the Company’s receipt of a letter from the Committee is incorporated in this Item 8.01 by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
JAGUAR HEALTH, INC.
|
|
|
|
Date: May 8, 2020
|
By:
|
/s/ Lisa A. Conte
|
|
Name: Lisa A. Conte
|
|
Title: Chief Executive Officer & President
|
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jul 2023 to Jul 2024